US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles
- The 'real-life Martha' from Baby Reindeer bombarded Sir Keir Starmer with almost 300 emails, it has2024-05-21
National candidate heads to easy victory in Port Waikato by
Andrew Bayly Photo: RNZ / Samuel Rillstone2024-05-21Invasive fish species likely illegally released in Kāpiti lakes
The discovery of dead tench in two Paraparaumu lakes suggests the invasive species has been illegall2024-05-21Trump poised for billions as stock market deal passes
By Natalie Sherman, BBC Business reporter, New YorkFormer US president Donald Trump could soon benef2024-05-21Not so Cool Britannia! Noel Gallagher gives damning verdict on Keir Starmer
Noel Gallagher has insisted he would still back Tony Blair for PM - as he warned Keir Starmer not to2024-05-21Tauranga boarding house fails healthy homes standards, owner ordered to pay tenants
Residents of the 21-bedroom house were mostly made up of ex-prisoners on parole or the homeless requ2024-05-21
atest comment